Phase Forward Customer GlaxoSmithKline Signs Multi-Year Agreements

WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GlaxoSmithKline (GSK) has signed multi-year, multi-million dollar contracts covering Licensing and Study Support Services. GSK and Phase Forward also have a multi-year agreement in place for hosting services. Under the terms of the newly signed agreements, GSK will continue to utilize Phase Forward’s InForm™ Integrated Trial Management (ITM) solution. Since 2004, GSK has initiated nearly 600 clinical trials with Phase Forward’s InForm electronic data capture solution and utilizing Phase Forward’s hosting and study support services.